PLCXD3

Across TCGA pan-cancer cohorts, PLCXD3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of PLCXD3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where PLCXD3 RNA is repressed in tumor relative to normal tissue. In most cancer types PLCXD3 is over-expressed in tumor, although a few such as KIRP and COAD show the opposite, repressed pattern.

KIRP, COAD, and KIRC are the cancer types where PLCXD3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCXD3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Female	II,III,IV	−2.714	<.001	11	view →
COAD	All	III,IV	−0.688	<.001	11	view →
KIRC	Male	All	−1.733	<.001	9	view →
THCA	Male	II,III,IV	−0.971	<.001	9	view →
UCEC	All	All	−1.580	<.001	8	view →
STAD	Male	All	−1.021	<.001	8	view →
HNSC	Male	IV	−0.444	<.001	8	view →
LUSC	Female	II,III,IV	−1.680	<.001	7	view →
LUAD	Female	III,IV	−1.286	<.001	7	view →
BRCA	All	III,IV	−1.181	<.001	6	view →
LIHC	All	All	−0.461	<.001	5	view →
KICH	Male	II,III,IV	−1.313	.006	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

PLCXD3–KIRP

Open the KIRP breakdown →